ProQR Therapeutics (PRQR) Financials: History & Chart

ProQR Therapeutics N.V.(PRQR)

Biotechnology · Leiden, ZH

$1.65-0.02 (-1.20%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

Leiden, ZH

166 employees

www.proqr.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Anton de Boer

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	21.48M	10.17M	2.39M	5.51M	3.42M	4.50M	4.89M	4.46M	4.28M
Cost of Goods Sold	1.64M	821K	815K	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	19.85M	9.35M	1.57M	5.51M	3.42M	4.50M	4.89M	4.46M	4.28M
Gross Profit Margin	92.4%	91.9%	65.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	70.05M	19.59M	17.60M	16.19M	16.66M	18.94M	16.58M	14.90M	13.98M
Research & Development	53.25M	14.71M	13.89M	11.65M	13.00M	13.45M	13.33M	10.99M	10.48M
Selling, General & Administrative	17.57M	4.88M	4.45M	4.57M	3.66M	5.68M	3.50M	4.05M	3.66M
Operating Income (EBIT)	-50.20M	-10.24M	-16.03M	-10.69M	-13.24M	-14.44M	-11.70M	-10.44M	-9.70M
Operating Margin	-233.6%	-100.7%	-671.4%	-194.0%	-387.1%	-320.9%	-239.3%	-234.1%	-226.8%
Income Before Tax (EBT)	-49.21M	-10.10M	-15.72M	-10.48M	-12.91M	-14.33M	-10.90M	-9.64M	-9.03M
Interest Income	809K	176K	249K	N/A	384K	226K	492K	729K	522K
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	986K	138K	312K	209K	326K	104K	797K	804K	677K
Net Income	-49.24M	-10.13M	-15.72M	-10.48M	-12.91M	-14.36M	-10.90M	-9.64M	-9.03M
Income Tax Expense	30K	29K	0.00	1K	0.00	21K	0.00	0.00	0.00
Net Profit Margin	-229.2%	-99.6%	-658.3%	-190.3%	-377.6%	-319.1%	-223.0%	-216.0%	-211.0%
EBITDA	-46.98M	-9.42M	-15.21M	-9.89M	-12.45M	-13.64M	-10.96M	-9.74M	-8.94M
EBITDA Margin	-218.7%	-92.6%	-637.2%	-179.6%	-364.1%	-303.2%	-224.3%	-218.5%	-208.9%
Depreciation & Amortization	3.22M	821K	815K	798K	787K	796K	733K	695K	766K
EPS Basic	-0.46	-0.09	-0.15	-0.10	-0.12	-0.14	-0.11	-0.11	-0.11
EPS Diluted	-0.46	-0.09	-0.15	-0.10	-0.12	-0.14	-0.11	-0.11	-0.11
Weighted Average Basic Shares	109.96M	109.96M	105.36M	103.01M	105.35M	105.34M	105.30M	81.67M	81.67M
Weighted Average Diluted Shares	109.96M	109.96M	105.36M	103.01M	110.06M	105.34M	105.30M	81.67M	81.67M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	17.95M	19.58M	7.19M	3.85M	1.52M	1.26M	2.17M	5.65M
Cost of Goods Sold	3.05M	0.00	0.00	0.00	0.00	0.00	131.10M	1.13M
Gross Profit	14.90M	19.58M	7.19M	3.85M	1.52M	1.26M	-128.93M	4.53M
Gross Profit Margin	83.0%	100.0%	100.0%	100.0%	100.0%	100.0%	-5943.6%	80.1%
Total Operating Expenses	64.41M	51.13M	42.35M	73.56M	66.64M	53.01M	66.64M	48.13M
Research & Development	47.83M	37.65M	27.76M	54.42M	48.06M	46.58M	52.17M	33.78M
Selling, General & Administrative	17.69M	14.15M	17.92M	19.96M	19.77M	16.72M	14.46M	14.35M
Operating Income (EBIT)	-49.51M	-31.55M	-35.16M	-69.72M	-65.13M	-51.76M	-64.47M	-41.54M
Operating Margin	-275.9%	-161.2%	-489.1%	-1813.0%	-4285.4%	-4117.4%	-2971.8%	-734.5%
Income Before Tax (EBT)	-47.57M	-28.95M	-30.70M	-68.59M	-69.08M	-56.79M	-63.53M	-42.44M
Interest Income	2.63M	3.37M	2.86M	113K	6K	382K	451K	-906K
Interest Expense	1.02M	1.12M	1.33M	5.49M	3.88M	2.49M	1.22M	927K
Other Income/Expense	1.94M	2.60M	4.47M	1.12M	-3.95M	-5.04M	132.03M	-906K
Net Income	-47.59M	-28.75M	-31.04M	-68.93M	-69.14M	-56.88M	-63.68M	-42.22M
Income Tax Expense	21K	-204K	-86K	103K	133K	151K	148K	1K
Net Profit Margin	-265.2%	-146.9%	-431.7%	-1792.5%	-4549.8%	-4525.3%	-2935.6%	-746.7%
EBITDA	-46.47M	-28.69M	-32.39M	-67.02M	-62.47M	-48.88M	-62.17M	-40.41M
EBITDA Margin	-258.9%	-146.6%	-450.5%	-1742.8%	-4110.9%	-3888.5%	-2866.0%	-714.6%
Depreciation & Amortization	3.05M	2.86M	2.77M	2.70M	2.65M	2.88M	2.30M	1.13M
EPS Basic	-0.45	-0.35	-0.39	-0.97	-1.09	-1.14	-1.55	-1.24
EPS Diluted	-0.45	-0.35	-0.39	-0.97	-1.09	-1.14	-1.55	-1.24
Weighted Average Basic Shares	105.33M	81.67M	81.01M	71.64M	64.18M	50.06M	41.04M	34.05M
Weighted Average Diluted Shares	105.33M	81.67M	81.01M	71.64M	64.18M	50.06M	41.04M	34.05M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.